Active Filter(s):
Details:
Scientists found that combining the drug with another protein inhibitor leads to insurmountable DNA damage that causes cancer cells to die.
Lead Product(s): SRA737,Momelotinib,Aphidicolin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2020